Aruinia discloses FDA information request on Lupkynis amid top regulator’s exit

2 hours ago 1
US Food and Drug Administration (FDA)

With its Q3 2025 results on Tuesday, Aurinia Pharmaceuticals (AUPH) said that it recently responded to an information request from the U.S. FDA regarding its lead drug, Lupkynis, which has led to a leadership shake-up at the agency with the exit of

Recommended For You

More Trending News

Read Entire Article